Led by OPAZ, OPGM 2026 connects companies with Oman’s pharma, healthcare, investment and manufacturing opportunities across its economic zones, free zones and industrial cities.
OPGM 2026 is Oman’s focused pharma and healthcare business mission to India, led by OPAZ. OPGM brings Oman’s Investment, Free Zone, Export, Industrial and Healthcare related Stakeholders to New Delhi to meet Indian Companies, Suppliers, Investors, Regulators, Policy Bodies and Sector Partners.
Convert the India - Oman CEPA Corridor into practical business conversations across Trade, Supply, Capital, Technology, Manufacturing and FDI.
The Public Authority for Special Economic Zones and Free Zones — OPAZ is leading Oman’s participation in OPGM 2026.
OPAZ brings together Oman’s special economic zones, free zones and investment ecosystem to help serious companies explore where and how they can engage with Oman.
Oman is a stable, connected and investor-friendly platform for pharma and healthcare companies seeking access to the GCC, Africa, Middle East and wider growth markets.
With economic zones, free zones, ports, logistics infrastructure and investment facilitation, Oman offers a practical base to supply, establish, manufacture, distribute and export.
You can access a combined consumer base of over 2.2 billion, from Oman.
Pharma is emerging as a strategic opportunity within Oman’s move towards high-value manufacturing and integrated healthcare industries. Investment opportunities span the value chain, including:
OPGM begins with pharma, with the potential to build future sector-growth missions for Oman.
The Comprehensive Economic Partnership Agreement (CEPA) between India and Oman creates a stronger framework for expanding bilateral trade and investment.
OPAZ’s 2026–2030 Five-Year Plan identifies the activation of CEPA with India, alongside increasing investment flows, developing supply chains, facilitating investor partnerships and connecting businesses to global markets.
For Indian pharmaceutical companies, this creates a stronger case to look beyond exporting into Oman and consider opportunities in manufacturing, localisation, supply-chain integration and regional market expansion.
Supply to Oman | Establish in Oman | Serve larger markets from Oman
Connect Indian suppliers with Oman’s demand for Medicines, Formulations, APIs, Instruments & Disposables.
Identify Companies, Investors and Technology Providers that can support Oman’s pharma-sector development.
Engage companies that can establish operations in Oman and serve regional and global markets from Oman.
Oman provides pharmaceutical investors with an integrated logistics environment designed to support the movement of products across regional and international markets.
Water desalination and treatment support pharmaceutical manufacturing.
Environmental permitting covers air, water and soil quality, waste and chemical management, emissions control and monitoring.
Digital systems, monitoring stations, drones and sensors support environmental oversight.
Renewable energy, green hydrogen, carbon capture, recycling and resource-efficiency initiatives support the transition towards a low-carbon economy.
Permitting, monitoring, data exchange and harmonised requirements help streamline environmental compliance across economic, free and industrial zones.
Strategic seaports such as Port of Duqm and Sohar Port, providing access to international shipping routes and global markets.
Integrated industrial and logistics hubs, particularly Sohar Free Zone, which combines advanced infrastructure, logistics services and proximity to global maritime transport networks.
Air connectivity through Muscat Airport Free Zone, supporting faster cargo handling and reduced transit times for products requiring rapid supply chains, including pharmaceuticals.
Multimodal logistics, integrating air, sea and land transportation with economic and free zones through the Asyad ecosystem.
Specialised storage infrastructure, including ready-built dry and refrigerated storage facilities and opportunities for pharmaceutical warehousing.
Accelerated customs clearance and simplified customs procedures to facilitate the movement of goods.
100% foreign ownership
Tax exemptions for up to 30 years
No minimum capital requirement
Usufruct agreements of up to 50 years, renewable
Customs exemptions on raw materials and equipment
Up to 30% of the Ministry of Health's requirement for the product
30% price preference for qualifying full manufacturing in government tenders
20% price preference for secondary packaging
Freedom to transact in all currencies
Access Oman’s growing healthcare market through supply, partnerships and investment.
Oman’s healthcare ecosystem, supported by the Ministry of Health (MOH), Oman, presents recurring demand across pharmaceuticals, formulations, renal care, diagnostics, surgical consumables, medical instruments and hospital supplies. OPGM 2026 connects Indian companies with opportunities to enter the Omani market, establish local partnerships and build a long-term presence.
Explore Opportunities to:
Access healthcare procurement and market opportunities across pharmaceuticals, medical products and hospital supplies.
Explore product registration, distribution and commercial partnership opportunities in Oman.
Develop stocking, servicing and healthcare supply-chain capabilities to support the Omani market.
Explore secondary packaging, assembly and other local value-addition opportunities.
Establish long-term manufacturing operations and investment in Oman’s growing healthcare ecosystem.
Use Oman as a strategic platform to access the GCC, Africa and wider international markets.
Supply to Oman | Partner in Oman | Establish in Oman | Grow into Regional Markets
With over USD 600 million in pharmaceutical investments, Salalah Free Zone is home to major projects including Philex Pharmaceuticals, Dhofar Pharmaceutical Industries Company SAOG, the International Pharmaceutical Complex, and Oman Pharmaceutical Products (OPP).
A USD 150 million investment with an annual production capacity of 1 billion tablets and capsules.
Exports pharmaceutical products to more than 50 countries worldwide.
Opened a new manufacturing facility in Raysut in 2024.
Specialises in oncology and rare-disease treatments and was established in 2024.
Indian and global companies across:
Connect with Oman if you are looking to:
Supply to Oman Partner with Oman Invest in Oman Manufacture in Oman
Use Oman to serve GCC, Africa, Middle East and wider markets
With Oman’s pharmaceutical market projected to reach USD 1.24 billion by 2031 and approximately 11 major pharmaceutical projects and manufacturing facilities operating across its zones, the sector presents opportunities for companies planning their next stage of growth.
